RFP QuestBeta
OpenStage · award

CELL AND GENE THERAPY CATAPULT

Ribosome profiling of suspension-adapted HEK293 cells producing adeno-associated viruses

R&DCPV 73111000
ValueValue not published
Deadline
Published13 Sept 2022
RegionNationwide
Who to contact
procurement@ct.catapult.org.uk

The procurement contact named on the official notice.

Match for your company
Sign up free to see how well this tender matches your company — the score, the signals that align, and where the gaps are.
The brief

Services for the ribosome profiling of suspension-adapted human cells producing an adeno-associated virus (AAV) vector.Human cells will be subjected to AAV production in parallel with controls.

A range of samples (between 21 and 35) will be generated in this experiment, designated as "Run 1".

The samples will then be processed by the awarded Bidder.

In addition to "Run 1", two additional runs ("Run 2" and "Run 3") may be performed at our sole discretion.

Importantly, the experimental setup for both "Run 2" and "Run 3" will be similar to that for "Run 1", but sample numbers may differ if additional conditions are included or excluded.

A maximum of 35 samples will be obtained for either "Run 2" and "Run 3".

Buyer intelligence

Make the case to bid

Reveal who to approach at CELL AND GENE THERAPY CATAPULT, and generate a go-to-market strategy from their news, accounts and people.

Source & provenance
OCID
ocds-h6vhtk-034db7
Stage
award · Awarded
Source
Find a Tender
Buyer ref
025600-2022
View the original notice on Find a Tender

Contains public sector information licensed under the Open Government Licence v3.0. Source data © Crown copyright.

Market context

Who wins this kind of work

The suppliers and buyers around this opportunity — drawn from official award data. Drag to orbit; click a node to explore.

Top suppliers & buyers in Research & Development

Assembling the market network…

CELL AND GENE THERAPY CATAPULT’s tender network

Assembling the network…